Sawgrass Asset Management LLC Has $987,000 Holdings in Cencora, Inc. (NYSE:COR)

Sawgrass Asset Management LLC lessened its holdings in Cencora, Inc. (NYSE:COR) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,395 shares of the company’s stock after selling 680 shares during the quarter. Sawgrass Asset Management LLC’s holdings in Cencora were worth $987,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Exchange Traded Concepts LLC grew its holdings in shares of Cencora by 41.6% in the 3rd quarter. Exchange Traded Concepts LLC now owns 5,334 shares of the company’s stock worth $1,201,000 after purchasing an additional 1,568 shares during the last quarter. CX Institutional grew its holdings in shares of Cencora by 8.0% in the 3rd quarter. CX Institutional now owns 8,868 shares of the company’s stock worth $1,996,000 after purchasing an additional 654 shares during the last quarter. NBC Securities Inc. grew its holdings in shares of Cencora by 3.9% in the 3rd quarter. NBC Securities Inc. now owns 5,680 shares of the company’s stock worth $1,278,000 after purchasing an additional 211 shares during the last quarter. Swedbank AB grew its holdings in Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after acquiring an additional 31,104 shares during the last quarter. Finally, Regatta Capital Group LLC grew its holdings in Cencora by 0.7% during the 3rd quarter. Regatta Capital Group LLC now owns 8,576 shares of the company’s stock worth $1,930,000 after acquiring an additional 61 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Trading Down 1.3 %

NYSE COR opened at $243.55 on Thursday. The firm has a market capitalization of $47.07 billion, a P/E ratio of 34.64, a PEG ratio of 1.49 and a beta of 0.49. The business has a fifty day simple moving average of $238.70 and a 200 day simple moving average of $237.21. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, analysts predict that Cencora, Inc. will post 15.36 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be given a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.90%. Cencora’s payout ratio is 31.29%.

Insider Buying and Selling

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $243.97, for a total value of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares in the company, valued at $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 73,187 shares of company stock worth $17,790,912 in the last quarter. 10.80% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a report on Friday, January 24th. Robert W. Baird upped their target price on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company upped their target price on shares of Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. UBS Group upped their target price on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Barclays increased their price target on shares of Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $277.90.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.